Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Slides:

Advertisements

Similar presentations

OSTEOPOROSIS CHOICE Decision Aid

Advertisements

FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.

Practical Recommendations for COPD:

The Future of Osteoporosis: Improving Care Along the Way

The Nurse View Key Insights Along the CML Continuum

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Diagnosing Vertebral Fractures

UNDERSTANDING RISK STRATIFICATION IN PAH:

Assessment of Vertebral Fractures

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Patient 1: 53-Year-Old Man With CVD Risk Factors

American Heart Association Scientific Sessions

Statins and the Elderly Patient

Bone Biology and Osteoporosis: Back to the Basics

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

New Treatments for CTEPH

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Clinical Considerations in Evidence-based Management of GIST

Lessons Learned In Opioid Treatment From the Pain Action Consulting Team.

When Would You Use Single Inhaler Triple Therapy in COPD?

PAH Therapy Revisited.

Guidance for Bone Health in Parkinson's

Checkpoint Inhibition

Treating HFrEF: Challenges Faced

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Are We Closer to Personalized Medicine in MS?

HCV Protease Inhibitors in Clinical Practice

Postpartum Depression

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Understanding PAD.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

The Importance of Getting the Dose Right in HF

Advancing the Treatment of IBD With Biologics

Best Practices in the Identification and Management of Alzheimer Agitation.

Deciding on Pharmacological Treatment Post Fracture

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Bone Biology and Osteoporosis: Back to the Basics

The Evolving Treatment Landscape in Atopic Dermatitis

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Oral Prostanoids and PAH

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Program Goals Overview Is NEDA a Reasonable Target?

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

The Road to Quality Improvement in HER2-Positive Breast Cancer

Deciding on Pharmacological Treatment Post Fracture

When Is Intrathecal Drug Delivery Appropriate?

Managing Age-Related Clinical Issues in Hemophilia

New ELN Recommendations

Patient Questions and Expert Answers in Psoriasis:

HCV Protease Inhibitors in Clinical Practice

Bone Biology and Osteoporosis: Back to the Basics

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Communicating With Your Patients About Major Depressive Disorder

Incorporating Prostacyclins Into Practice

Improving Adherence to Antiplatelet Therapy After an ACS Event

The Patient With Early Stage MF-CTCL

Assessing the Burden of Hyperkalemia

Program Goal. Program Goal Disclaimer Overview.

AMD Therapy: Where Are We Now and Where Are We Going?

Assessing the Burden of Hyperkalemia

Clinical Considerations in Evidence-based Management of GIST

PAH Pathways: What Do the Data Tell Us?”

Clinical Comparisons in CTEPH

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Practical Recommendations for COPD:

Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.

Presentation transcript:

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture

Secondary Osteoporosis

Indications for Vertebral Imaging

Osteoporosis Definitions

Adverse Effects of Secondary Causes of Osteoporosis

Who Needs a Workup?

Calcium Calculator

Universal Management Recommendations

FRAX: Calculate 10-Year Fracture Probability

Drug Therapies

Treatment Is Effective, but Not Ideal

New Approaches to Treatment

Conclusion

Abbreviations

References

References (cont)

References (cont)

References (cont)